SynthesisQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2025
An international compendium of health state utilities in people with HIV: a systematic review.
Synthesis in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeMeasuring health-related quality of life across different health states for people with HIV (PWH) using direct or indirect preference-based values can inform decision-analytic models evaluating cost-effectiveness of different care strategies. This systematic literature review collates comprehensive international evidence on health state utility values (HSUVs) in PWH to inform economic modelling of antiretroviral therapies (ARTs).
methodsThis review aligns with PRISMA standards (PROSPERO: CRD42022346286). Searches from multiple sources (e.g. MEDLINE, EMBASE) identified HSUVs for PWH from 2000. We categorised HSUVs using ISPOR's Task Force criteria from low (high bias risk) to high (low bias risk) quality, alongside National Institute for Health and Care Excellence (NICE) suitability grading from Grade 3 (did not meet necessary criteria) to 1 (no concerns). Tabular and narrative syntheses were undertaken.
resultsOverall, 53 studies from 22 countries were identified. Study sizes ranged from 32 to 4137 participants. HSUVs were from cross-sectional (n = 45) or longitudinal (n = 10) datasets, stratified by infection stage, CD4 count, viral load, and treatment status. EQ-5D three-level (n = 29) and five-level (n = 18) estimates were most common. Although 28 included studies were 'high' quality, most were Grade 3 for NICE suitability, mainly indicating that the HSUVs for these studies were not representative of a UK population. Extensive methodological and clinical heterogeneity precluded meta-analysis.
conclusionsGreater clarity in treatment regimens, preference-weighting methods, and different HIV clinical stages could improve interpretation and applicability of HSUVs in economic models. Despite this, our compendium and taxonomy of HSUVs can inform ART economic modelling within relevant populations and different jurisdictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.